Complement C5 (Complement 5)

C5 plays a central role in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C5 is cleaved by C5 CONVERTASE into COMPLEMENT C5A and COMPLEMENT C5B. The smaller fragment C5a is an ANAPHYLATOXIN and mediator of inflammatory process. The major fragment C5b binds to the membrane initiating the spontaneous assembly of the late complement components, C5-C9, into the MEMBRANE ATTACK COMPLEX.

Also Known As:

Networked: 270 relevant articles (19 outcomes, 35 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Todaro, Thomas G: 7 articles (07/2011 - 09/2003)
2.	Mollnes, Tom Eirik: 6 articles (01/2021 - 07/2011)
3.	Shernan, Stanton K: 5 articles (07/2011 - 03/2004)
4.	Nunn, Miles A: 4 articles (01/2022 - 01/2013)
5.	Adams, Peter X: 4 articles (07/2011 - 08/2006)
6.	Chen, John C: 4 articles (07/2011 - 03/2004)
7.	Levy, Jerrold H: 4 articles (07/2011 - 08/2006)
8.	Verrier, Edward D: 4 articles (07/2011 - 06/2005)
9.	Rus, Horea: 4 articles (08/2009 - 09/2003)
10.	Granger, Christopher B: 4 articles (08/2006 - 09/2003)

Related Diseases

1.	Atypical Hemolytic Uremic Syndrome 01/01/2011 - "Targeting complement C5 in atypical hemolytic uremic syndrome." 01/01/2011 - "The development of atypical hemolytic uremic syndrome depends on complement C5." 06/01/2021 - "Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults." 01/01/2017 - "Treatment of atypical hemolytic uremic syndrome (aHUS) by the complement C5 inhibitor eculizumab (Soliris®) is highly effective but unfortunately, associated with an economic pressure on the health care systems even in high incomes countries. " 10/01/2015 - "Complement C5 inhibitor eculizumab treatment in atypical hemolytic uremic syndrome is effective, but associated with high costs. "
2.	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/01/2020 - "Complement C5 inhibition is the standard of care (SoC) for patients with paroxysmal nocturnal hemoglobinuria (PNH) with significant clinical symptoms. " 01/01/2020 - "The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria." 01/01/2021 - "Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria." 01/01/2022 - "Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study." 01/01/2023 - "Complement C5 inhibitor eculizumab is the first approved treatment for paroxysmal nocturnal hemoglobinuria (PNH), a rare hematologic disorder caused by uncontrolled terminal complement activation. "
3.	Inflammation (Inflammations) 01/01/2018 - "To assess the efficacy of the combined inhibition of complement (C5) and CD14 on systemic inflammation induced in a forceful piglet MAS model. " 01/01/2023 - "Dual inhibition of complement C5 and CD14 attenuates inflammation in a cord blood model." 01/01/2021 - "Combined blockade of complement C5 and TLR co-receptor CD14 synergistically inhibits pig-to-human corneal xenograft induced innate inflammatory responses." 10/01/2018 - "Avacincaptad pegol is a C5 complement inhibitor that may reduce inflammation-related RPE damage. " 01/01/2017 - "C1M (71.2±26.1 vs 46.2±6.2 nmol/L [P<.001]), C3M (31.6±3.9 vs 26.1±1.6 nmol/L [P=.002] and Pro-C5 levels (1171.7±171.5 vs 909.6±80.4 nmol/L [P=.002]) were higher in patients with active inflammation vs without active inflammation. "
4.	COVID-19 12/01/2020 - "Complement C5 inhibition in patients with COVID-19 - a promising target?" 08/09/2022 - "Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial." 11/01/2021 - "To investigate this, Macpherson et al. studied how knob domains attach to complement C5, a protein in the inflammatory pathway which is a drug target for various diseases, including severe COVID-19. " 11/01/2020 - "We present results from a nonrandomized proof-of-concept study of complement C5 inhibitor eculizumab for treatment of severe COVID-19. " 07/13/2020 - "Primary Objective • To evaluate the effect of ravulizumab, a long-acting complement (C5) inhibitor plus best supportive care (BSC) compared with BSC alone on the survival of patients with COVID-19. "
5.	Hemolysis 01/01/2022 - "Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study." 10/01/2015 - "The profound, life-threatening, intravascular hemolysis was rapidly and dramatically reduced with the Complement 5 (C5) inhibitory antibody, eculizumab. " 01/01/2019 - "Experiments using preassembled classical pathway C3 convertases confirmed that C4b2a directly activated complement component 5 (C5), leading to membrane attack complex formation and hemolysis. " 01/01/2020 - "Inhibition of complement component 5 (C5) with eculizumab has resulted in a significant reduction of hemolysis, reduction of thromboembolic events, and increased survival in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). " 12/01/2018 - "Eculizumab is a potent C5 complement inhibitor and reduces intravascular haemolysis and thrombosis in PNH patients and improves their quality of life. "

Related Drugs and Biologics

1.	eculizumab
2.	Monoclonal Antibodies
3.	Complement System Proteins (Complement)
4.	zilucoplan
5.	ravulizumab
6.	Antibodies
7.	Interleukin-6 Receptors (Interleukin 6 Receptor)
8.	Peptides (Polypeptides)
9.	Immunoglobulin Fc Fragments
10.	rozanolixizumab

Related Therapies and Procedures

1.	Therapeutics
2.	Cardiopulmonary Bypass (Heart-Lung Bypass)
3.	Artificial Respiration (Mechanical Ventilation)
4.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
5.	Percutaneous Coronary Intervention